Share on StockTwits

Apricus Biosciences (NASDAQ:APRI) released its earnings data on Tuesday. The company reported $0.05 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.04) by $0.09, AnalystRatingsNetwork reports. The company had revenue of $5.50 million for the quarter, compared to the consensus estimate of $5.45 million.

A number of research firms have recently commented on APRI. Analysts at Zacks downgraded shares of Apricus Biosciences from a “neutral” rating to an “underperform” rating in a research note on Wednesday, July 16th. They now have a $1.90 price target on the stock. Analysts at Cantor Fitzgerald upgraded shares of Apricus Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, May 27th. They now have a $3.00 price target on the stock, up previously from $2.50.

Apricus Biosciences (NASDAQ:APRI) opened at 1.97 on Tuesday. Apricus Biosciences has a one year low of $1.66 and a one year high of $2.71. The stock’s 50-day moving average is $2.03 and its 200-day moving average is $2.22. The company’s market cap is $74.6 million.

Apricus Biosciences, Inc, formerly NexMed, Inc, is a pharmaceutical research and development company focused on the design and development of products and technologies in multiple therapeutic areas, including oncology, sexual dysfunction, autoimmune diseases and pain/inflammation.

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.